Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients
- 1 April 2017
- journal article
- other
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 36 (4) , 435-437
Abstract
No published data are available regarding infliximab use in Kawasaki disease patients with recent live virus vaccination. We investigated 38 acute Kawasaki disease patients who received infliximab within 90 days of receiving measles-mumps-rubella, varicella-zoster virus, or Rotavirus vaccines. There were no adverse events or serious infections, which suggests that infliximab use in acute Kawasaki disease patients with recent live viral vaccinations is safe.Keywords
This publication has 10 references indexed in Scilit:
- Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's DiseaseJournal of Crohn's and Colitis, 2010
- Tumor necrosis factor blockade and the risk of viral infectionNature Reviews Rheumatology, 2010
- Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Resistance to Intravenous Immunoglobulin in Children with Kawasaki DiseaseThe Journal of Pediatrics, 2008
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Infliximab treatment for refractory Kawasaki syndromeThe Journal of Pediatrics, 2005
- Intravenous gamma-globulin treatment and retreatment in Kawasaki diseaseThe Pediatric Infectious Disease Journal, 1998
- A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki SyndromeNew England Journal of Medicine, 1991
- Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki diseaseClinical Immunology and Immunopathology, 1988